Am J Transplant, Volume 21, Suppl 3 Archives - Page 33 of 139 - ATC Abstracts

2021 American Transplant Congress
The Impact of Fixed-Dose Alemtuzumab in Renal Transplant Recipients According to Weight
S. Mandala¹, N. Khodieva², A. Bigness¹, S. Mohamed², H. Mohammed¹, K. Robichaux², A. Brueckner³, R. Baliga⁴, J. Buggs⁵, A. Kumar¹, L. Bowman³
¹Morsani College of Medicine, University of South Florida, Tampa, FL, ²Honors College, University of South Florida, Tampa, FL, ³Transplant Pharmacy, Tampa General Hospital, Tampa, FL, ⁴Nephrology, Florida Kidney Physicians, Tampa, FL, ⁵Transplant Surgery, Tampa General Hospital, Tampa, FL
*Purpose: Alemtuzumab, a potent anti-CD52 monoclonal antibody is used for induction immunosuppression post-renal transplantation as a fixed 30mg dose regardless of the patient’s weight. The…
2021 American Transplant Congress
Belatacept Utilization During the Covid-19 Pandemic in the United States
M. MacConmara, A. Shubin, D. Wojciechowski, L. de Gregorio, J. Shah, P. Vagefi, C. S. Hwang
Department of Surgery, Division of Surgical Transplantation, University of Texas Southwestern Medical Center, Dallas, TX
*Purpose: With the onset of the COVID-19 pandemic, many people in the United States were urged to stay at home. Kidney transplantation continued during this…
2021 American Transplant Congress
Patient Survival After Living Donor Kidney Donation
M. G. Naik, K. Sakurayama, K. Budde, F. Halleck
Medical Department, Division of Nephrology and Internal Intensive Care Medicine, Charité, Berlin, Germany
*Purpose: Living donor kidney transplantation [LDKT] is associated with best patient survival and life quality among kidney replacement therapies in case of chronic kidney disease.…
2021 American Transplant Congress
Kidney Transplant Associated Allergy Transfer After Living Donation
K. López-Vega, S. Davis
Division of Renal Diseases and Hypertension, Anschutz Medical Campus, University of Colorado, Aurora, CO
*Purpose: Donor to recipient IgE-mediated food allergy transfer has been described in non-kidney solid organ transplant. Here, we report a novel case of an adult…
2021 American Transplant Congress
Robotic Assisted Donor Nephrectomy: A Single Center Experience
A. Khan, A. Sharma, S. Lee, A. Cotterell, D. Kumar, L. Kamal, I. Moinuddin, D. Bruno, V. Kumaran, M. Levy, C. Bhati
Transplant Surgery, Virginia Commonwealth University, Richmond, VA
*Purpose: Robotic donor nephrectomy (RLDN) is an emerging procedure of choice for living kidney donors at many programs. This approach has benefit of minimal invasive…
2021 American Transplant Congress
Pediatric Kidney Transplant Strategy: The Sequence Effect
A. J. Vinson¹, B. Kiberd², P. Acott³, K. Tennankore¹
¹Nova Scotia Health Authority Division of Nephrology, Departm, Halifax, NS, Canada, ²Dalhousie University, Halifax, NS, Canada, ³IWK Health Center, Halifax, NS, Canada
*Purpose: Improvements in patient survival with pediatric end stage kidney disease (ESKD) predicts needing more than one kidney transplant over a child’s lifetime. Timing of…
2021 American Transplant Congress
Single Center Experience on SARS-CoV-2 Testing of Symptomatic and Asymptomatic Pediatric Kidney Transplant Recipients
H. Pizzo¹, P. R. Soni², S. Nadipuram², J. Garrison¹, D. Puliyanda¹
¹Pediatric Nephrology, Cedars-Sinai Medical Center, Los Angeles, CA, ²Pediatric Infectious Disease, Cedars-Sinai Medical Center, Los Angeles, CA
*Purpose: As of late November 2020, there have been 61.5 million cases of SARS-CoV-2 (COVID-19) worldwide resulting in 1.44 million deaths. Despite the outstanding number…
2021 American Transplant Congress
Graft Outcomes of Antibody Mediated Rejection without Donor Specific Anti – HLA Antibodies After Kidney Transplantation
H. Ko, S. Min, A. Han, S. Ahn, C. T. Chung, H. Kim, K. Choi, S. Min, H. Kang, J. Ha
Seoul National University Hospital, Seoul, Korea, Republic of
*Purpose: The aim of this study was to investigate graft outcomes based on the presence of donor-specific anti-HLA antibodies (DSA) and the time of diagnosis…
2021 American Transplant Congress
Clazakizumab for the Treatment of Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients: Phase 3 IMAGINE Study Design
P. Nickerson¹, G. Böhmig², S. Chadban³, D. Kumar⁴, R. B. Mannon⁵, T. van Gelder⁶, S. Adler⁷, E. Chong⁷, A. Djamali⁸
¹University of Manitoba, Winnipeg, MB, Canada, ²Medical University of Vienna, Vienna, Austria, ³University of Sydney, Sydney, Australia, ⁴University of Toronto, Toronto, ON, Canada, ⁵University of Nebraska Medical Center, Omaha, NE, ⁶Leiden University Medical Center, Leiden, Netherlands, ⁷CSL Behring, King of Prussia, PA, ⁸University of Wisconsin, Madison, WI
*Purpose: Chronic active antibody-mediated rejection (CAMR) is a major cause of allograft loss with no approved drugs for its treatment. Currently, off-label regimens recommended by…
2021 American Transplant Congress
Recurrence and Outcome of Anti-GBM Glomerulonephritis After Kidney Transplantation: A Belgian Multicenter Study
S. Coche
Nephrology, Cliniques Universitaires Saint-Luc, Brussels, Belgium
*Purpose: Recurrence of anti-glomerular basement membrane (anti-GBM) glomerulonephritis (GN) in the kidney graft is a rare event, described in limited case reports and registry analysis.…